Unknown

Dataset Information

0

Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.


ABSTRACT: Multidrug-resistant tuberculosis (MDR-TB) is a serious life threatening condition affecting children as well as adults worldwide. Timely diagnosis and effective treatment, both of which are complex in children, are the prerogatives for a favorable outcome. Areas covered: This review covers epidemiology, treatment regimen and duration, newer drugs and adverse events in children with MDR-TB. Special note has been made of epidemiology and principles of treatment followed in Indian children. Expert opinion: High index of suspicion is essential for diagnosing childhood MDR-TB. If there is high probability, a child can be diagnosed as presumptive MDR-TB and started on empiric treatment in consultation with experts. However, every effort should be made to confirm the diagnosis. Backbone of an effective MDR-TB regimen consists of four 2nd line anti-TB drugs plus pyrazinamide; duration being 18-24 months. The newer drugs delamanid and bedaquiline can be used in younger children if no other alternatives are available after consultation with experts. Wider availability of these drugs should be ensured for benefit to all concerned. More research is required for development of new and repurposed drugs to combat MDR-TB. Children need to be included in clinical trials for such life-saving drugs, so that nobody is denied the benefits.

SUBMITTER: Mukherjee A 

PROVIDER: S-EPMC5942143 | biostudies-other | 2017 Oct

REPOSITORIES: biostudies-other

altmetric image

Publications

Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Mukherjee Aparna A   Lodha Rakesh R   Kabra Sushil Kumar SK  

Expert opinion on pharmacotherapy 20171009 15


<h4>Introduction</h4>Multidrug-resistant tuberculosis (MDR-TB) is a serious life threatening condition affecting children as well as adults worldwide. Timely diagnosis and effective treatment, both of which are complex in children, are the prerogatives for a favorable outcome. Areas covered: This review covers epidemiology, treatment regimen and duration, newer drugs and adverse events in children with MDR-TB. Special note has been made of epidemiology and principles of treatment followed in Ind  ...[more]

Similar Datasets

| S-EPMC5526484 | biostudies-other
| S-EPMC8156326 | biostudies-literature
| S-EPMC4631605 | biostudies-literature
| S-EPMC5823351 | biostudies-literature
| S-EPMC5988693 | biostudies-literature
| S-EPMC2062482 | biostudies-literature
| S-EPMC4908783 | biostudies-literature
| S-EPMC4952541 | biostudies-literature
| S-EPMC4958188 | biostudies-literature
| S-EPMC4366580 | biostudies-literature